These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2948607)

  • 61. Pharmacological sex hormone manipulation as a risk model for depression.
    Frokjaer VG
    J Neurosci Res; 2020 Jul; 98(7):1283-1292. PubMed ID: 32399989
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.
    Aydiner A; Kilic L; Yildiz I; Keskin S; Sen F; Kucucuk S; Karanlik H; Muslumanoglu M; Igci A
    Med Oncol; 2013 Mar; 30(1):354. PubMed ID: 23275115
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
    Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
    Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical pharmacokinetics of goserelin.
    Cockshott ID
    Clin Pharmacokinet; 2000 Jul; 39(1):27-48. PubMed ID: 10926349
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
    Perry CM; Brogden RN
    Drugs; 1996 Feb; 51(2):319-46. PubMed ID: 8808170
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Successful treatment of infertility due to polycystic ovary disease using a combination of luteinising hormone releasing hormone agonist and low dosage menotrophin.
    Armitage M; Wilkin T; Dewbury K
    Br Med J (Clin Res Ed); 1987 Jul; 295(6590):96. PubMed ID: 3113653
    [No Abstract]   [Full Text] [Related]  

  • 68. Acne and psoriasis.
    Murphy GM; Greaves MW
    Br Med J (Clin Res Ed); 1988 Feb; 296(6621):546-8. PubMed ID: 2964889
    [No Abstract]   [Full Text] [Related]  

  • 69. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
    McClelland HR; Quinn AJ
    Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Treatment with the LH-RH agonist (Zoladex depot) in patients with puberty praecox].
    Bassi F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():33-7. PubMed ID: 2150502
    [No Abstract]   [Full Text] [Related]  

  • 72. Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist.
    Thomas EJ; Jenkins J; Lenton EA; Cooke ID
    Br Med J (Clin Res Ed); 1986 Nov; 293(6559):1407-8. PubMed ID: 2948607
    [No Abstract]   [Full Text] [Related]  

  • 73. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
    Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
    Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 75. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
    Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
    Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
    Matta WH; Shaw RW; Burford GD
    Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.